Quick Answer
Summit Therapeutics Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $0.00 for the year ending 2024.
- This data is from Summit Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2025.
- XBRL data for this metric is available from 2019 to 2024 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: $148.0 thousand | Q1 2020: $324.0 thousand | Q2 2020: $170.0 thousand | Q3 2020: $181.0 thousand | Q1 2021: $192.0 thousand | Q2 2021: $57.0 thousand | Q3 2021: $1.31 million | Q1 2022: $250.0 thousand | Q2 2022: $235.0 thousand | Q3 2022: $220.0 thousand | Q1 2023: $0.00 | Q2 2023: $0.00 | Q3 2023: $0.00 | Q3 2024: $0.00.
- Over the full 7 years of available data (2019 to 2024), Summit Therapeutics Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has declined by 100.0%.
- Historical annual values: Fiscal year 2024: $0.00 | Fiscal year 2023: $0.00 | Fiscal year 2022: $705.0 thousand | Fiscal year 2021: $1.81 million | Fiscal year 2020: $860.0 thousand | Fiscal year 2019: $743.0 thousand | Fiscal year 2019: $57.09 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: